Psoriatic Arthritis Epidemiology Summary
Psoriatic Arthritis Trends
· Psoriatic arthritis is generally a progressive condition, with a substantial proportion of patients developing structural joint damage over time if inadequately treated, despite advances in biologic therapy.
· As per National Psoriasis Foundation, roughly 1 in 3 people living with psoriasis also have psoriatic arthritis.
· Majority of patients fall under mild-to-moderate disease (~70–85%), while ~15–25% progress to severe disease.
· The disease typically affects adults aged 30–50 years, with a near equal male-to-female distribution, although males more frequently present with axial disease and females often report higher pain burden and functional impairment.
Psoriatic Arthritis Epidemiology Forecast in the 7MM
- 2025 Prevalent of Psoriatic Arthritis: ~XX
- 2036 Projected Psoriatic Arthritis prevalent Cases: ~XX
- Psoriatic Arthritis Growth Rate (2026–2036): ~XX% CAGR
DelveInsight's ‘Psoriatic Arthritis – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the psoriatic arthritis, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period
|
2022–2036
|
|
Historical Year
|
2022–2025
|
|
Forecast Period
|
2026–2036
|
|
Base Year
|
2026
|
|
Geographies Covered
|
· North America : The US;
· Europe: Germany, France, Italy, and Spain and the UK;
· Asia-Pacific: Japan;
|
|
Psoriatic Arthritis Epidemiology CAGR
(Forecast period)
|
~XX% (2026–2036)
|
|
Psoriatic Arthritis Epidemiology Segmentation Analysis
|
Patient Burden Assessment
- Psoriatic Arthritis Total Prevalent Cases
- Psoriatic Arthritis Total Diagnosed Prevalent Cases
- Psoriatic Arthritis Diagnosed Prevalent Cases by Gender
- Psoriatic Arthritis Diagnosed Prevalent Cases by Age
- Psoriatic Arthritis Diagnosed Prevalent Cases by Severity
- Psoriatic Arthritis Treated Cases
|
Psoriatic Arthritis Understanding and Diagnosis Algorithm
Psoriatic Arthritis Overview
Psoriatic arthritis is a chronic immune-mediated inflammatory disease that affects both the skin and joints and is strongly associated with psoriasis. It is characterized by joint pain, swelling, stiffness, enthesitis (inflammation at tendon/ligament insertion sites), and dactylitis (sausage digits). The disease follows a heterogeneous course, ranging from mild peripheral arthritis to severe erosive joint damage and axial involvement. Early diagnosis is critical because irreversible structural damage can occur if treatment is delayed.
Further details are provided in the report.
Psoriatic Arthritis Diagnosis
Diagnosis of psoriatic arthritis is primarily clinical, supported by classification criteria such as the CASPAR (Classification Criteria for Psoriatic Arthritis), which includes evidence of psoriasis, nail changes, negative rheumatoid factor, dactylitis, and radiographic findings. Imaging techniques like X-ray, ultrasound, and MRI help detect joint inflammation, erosions, and enthesitis at an early stage. Laboratory tests are mainly used to exclude other conditions like rheumatoid arthritis, as there is no single definitive biomarker for psoriatic arthritis.
Further details are provided in the report.
Psoriatic Arthritis Epidemiology
Key Findings from Psoriatic Arthritis Epidemiological Analysis and Forecast
· Globally, psoriatic arthirtis prevalence at approximately 0.1–0.2%.
· Approximately 2.4 million individuals in the United States are living with psoriatic arthritis, representing the prevalent patient population burden of the disease.
· More than 15% of people living with psoriasis may also have undiagnosed psoriatic arthritis in United States.
· The average age of onset of psoriatic arthritis is 30–50 years.
· Among patients with psoriasis, approximately 20% develop psoriatic arthritis, although this proportion varies according to age, disease severity, classification criteria, and region.
Scope of the Report
- The report covers a segment of a descriptive overview of psoriatic arthritis, explaining their causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Psoriatic Arthritis Patient Population Forecast
Report Key Strengths
- Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
- 11-year Forecast
- Patient Burden Trends (By Geography)
FAQs
- What are the disease risks, burdens, and unmet needs of psoriatic arthritis? What will be the growth opportunities across the 7MM concerning the patient population with psoriatic arthritis?
- What is the historical and forecasted psoriatic arthritis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Epidemiology Methodology of Psoriatic Arthritis
5 Psoriatic Arthritis Epidemiology Overview at a Glance
5.1 Patient Share (%) Distribution by Country in 2025 in the 7MM
5.2 Patient Share (%) Distribution by Country in 2036 in the 7MM
6 Disease Background And Overview of Psoriatic Arthritis
6.1 Introduction
6.2 Causes
6.3 Signs And Symptoms
6.4 Diagnosis
6.4.1 Differential Diagnosis
6.4.2 Diagnostic Algorithm
6.5 Diagnosis
6.5.1 Treatment Algorithm
6.5.2 Treatment Guidelines
7 Epidemiology and Patient Population of Psoriatic Arthritis
7.1 Key Findings
7.2 Assumption and Rationale
7.3 Psoriatic Arthritis Total Prevalent Cases in the 7MM
7.4 The United States
7.4.1 Psoriatic Arthritis Total Prevalent Cases in the United States
7.4.2 Psoriatic Arthritis Total Diagnosed Prevalent Cases in the United States
7.4.3 Psoriatic Arthritis Diagnosed Prevalent Cases by Gender in the United States
7.4.4 Psoriatic Arthritis Diagnosed Prevalent Cases by Age in the United States
7.4.5 Psoriatic Arthritis Diagnosed Prevalent Cases by Severity in the United States
7.4.6 Psoriatic Arthritis Treated Cases in the United States
7.5 EU4 and the UK
7.5.1 Psoriatic Arthritis Total Prevalent Cases in EU4 and the UK
7.5.2 Psoriatic Arthritis Total Diagnosed Prevalent Cases in EU4 and the UK
7.5.3 Psoriatic Arthritis Diagnosed Prevalent Cases by Gender in EU4 and the UK
7.5.4 Psoriatic Arthritis Diagnosed Prevalent Cases by Age in EU4 and the UK
7.5.5 Psoriatic Arthritis Diagnosed Prevalent Cases by Severity in EU4 and the UK
7.5.6 Psoriatic Arthritis Treated Cases in EU4 and the UK
7.6 Japan
7.6.1 Psoriatic Arthritis Total Prevalent Cases in Japan
7.6.2 Psoriatic Arthritis Total Diagnosed Prevalent Cases in Japan
7.6.3 Psoriatic Arthritis Diagnosed Prevalent Cases by Gender in Japan
7.6.4 Psoriatic Arthritis Diagnosed Prevalent Cases by Age in Japan
7.6.5 Psoriatic Arthritis Diagnosed Prevalent Cases by Severity in Japan
7.6.6 Psoriatic Arthritis Treated Cases in Japan
8 Patient Journey of Psoriatic Arthritis
9 KOL Views of Psoriatic Arthritis
10 Appendix
10.1 Bibliography
10.2 Report Methodology
11 DelveInsight Capabilities
12 Disclaimer
13 About DelveInsight
List of Tables:
List of Tables
Table 1: Summary of PsA, Epidemiology, and Key Events (2022-2036)
Table 2: Role of HLA Genes in PsA
Table 3: Role of non-HLA Genes in PsA
Table 4: CASPAR Criteria
Table 5: Moll and Wright Classification
Table 6: Operational Definition of Classification of PsA
Table 7: Suggested Diagnostic Algorithm
Table 8: Clinical Characteristics of Different Types of Arthritis That Can Aid Differential Diagnosis
Table 9: 2018 ACR/NPF Recommendations for the Initial Treatment for Active PsA who are OSM‐ and Other Treatment-naive
Table 10: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With a TNFi Biologics
Table 11: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With an IL‐17i or an IL‐12/23i Biologics
Table 12: 2018 ACR/NPF Recommendations for PsA Including Treat‐to‐target, Active Axial Disease, Enthesitis, or Active IBD
Table 13: 2018 ACR/NPF Recommendations for PsA and Comorbidities, Including Concomitant Diabetes and Recurrent Serious Infections
Table 14: 2018 ACR/NPF Recommendations for Non-pharmacologic Interventions in Patients With Active PsA Regardless of Pharmacologic Treatment Status
Table 15: Summary of Differences in Recommendations
Table 16: 2019 EULAR Overarching Principles
Table 17: 2019 EULAR Recommendations for the Pharmacological Management of PsA
Table 18: Total Prevalent Cases of PsA in the 7MM (2022-2036)
Table 19: Prevalent cases of PsA in the United States (2022-2036)
Table 20: Diagnosed Cases of PsA in the United States (2022-2036)
Table 21: Gender-specific Cases of PsA in the United States (2022-2036)
Table 22: Age-specific Cases of PsA in the United States (2022-2036)
Table 23: Severity-specific cases of PsA in the United States (2022-2036)
Table 24: Prevalent Cases of PsA in the EU5 (2022-2036)
Table 25: Diagnosed cases of PsA in Germany (2022-2036)
Table 26: Gender-specific Cases of PsA in Germany (2022-2036)
Table 27: Age-specific Cases of PsA in Germany (2022-2036)
Table 28: Severity-specific cases of PsA in Germany (2022-2036)
Table 29: Diagnosed cases of PsA in France (2022-2036)
Table 30: Gender-specific Cases of PsA in France (2022-2036)
Table 31: Age-specific Cases of PsA in France (2022-2036)
Table 32: Severity-specific cases of PsA in France (2022-2036)
Table 33: Diagnosed cases of PsA in Italy (2022-2036)
Table 34: Gender-specific Cases of PsA in Italy (2022-2036)
Table 35: Age-specific Cases of PsA in Italy (2022-2036)
Table 36: Severity-specific cases of PsA in Italy (2022-2036)
Table 37: Diagnosed cases of PsA in Spain (2022-2036)
Table 38: Gender-specific Cases of PsA in Spain (2022-2036)
Table 39: Age-specific Cases of PsA in Spain (2022-2036)
Table 40: Severity-specific cases of PsA in Spain (2022-2036)
Table 41: Diagnosed cases of PsA in the UK (2022-2036)
Table 42: Gender-specific Cases of PsA in the UK (2022-2036)
Table 43: Age-specific Cases of PsA in the UK (2022-2036)
Table 44: Severity-specific cases of PsA in the UK (2022-2036)
Table 45: Prevalent cases of PsA in Japan (2022-2036)
Table 46: Diagnosed Cases of PsA in Japan (2022-2036)
Table 47: Gender-specific Cases of PsA in Japan (2022-2036)
Table 48: Age-specific Cases of PsA in Japan (2022-2036)
Table 49: Severity-specific cases of PsA in Japan (2022-2036)
List of Figures:
List of Figures
Figure 1: Clinical Presentations of PsA
Figure 2: Classification of PsA
Figure 3: Risk Factors
Figure 4: Role of Obesity and Risk of Cardiovascular Comorbidities in PsA patients
Figure 5: Key cell Types and Secretion of key Inflammatory Mediators in PsA
Figure 6: Adaptive and Innate Immune Cells and Activated Pathways in PsA
Figure 7: Diagnosis of PsA
Figure 8: Radiographic Features of PsA
Figure 9: Differential Diagnosis
Figure 10: Pharmacologic, Non-pharmacologic, and Symptomatic Therapies for PsA
Figure 11: The EULAR 2019 Algorithm for Treatment of PsA With Pharmacological Non-topical Treatments
Figure 12: PsA Treatment Pathway Following Inadequate Response to DMARDs (NICE)
Figure 13: Total Prevalent Cases of PsA in the 7MM (2022-2036)
Figure 14: Prevalent cases of PsA in the United States (2022-2036)
Figure 15: Diagnosed Cases of PsA in the United States (2022-2036)
Figure 16: Gender-specific cases of PsA in the United States (2022-2036)
Figure 17: Age-specific Cases of PsA in the United States (2022-2036)
Figure 18: Severity-specific Cases of PsA in the United States (2022-2036)
Figure 19: Prevalent Cases of PsA in the EU5 (2022-2036)
Figure 20: Diagnosed cases of PsA in Germany (2022-2036)
Figure 21: Gender-specific cases of PsA in Germany (2022-2036)
Figure 22: Age-specific Cases of PsA in Germany (2022-2036)
Figure 23: Severity-specific Cases of PsA in Germany (2022-2036)
Figure 24: Diagnosed cases of PsA in France (2022-2036)
Figure 25: Gender-specific cases of PsA in France (2022-2036)
Figure 26: Age-specific Cases of PsA in France (2022-2036)
Figure 27: Severity-specific Cases of PsA in France (2022-2036)
Figure 28: Diagnosed cases of PsA in Italy (2022-2036)
Figure 29: Gender-specific cases of PsA in Italy (2022-2036)
Figure 30: Age-specific Cases of PsA in Italy (2022-2036)
Figure 31: Severity-specific Cases of PsA in Italy (2022-2036)
Figure 32: Diagnosed cases of PsA in Spain (2022-2036)
Figure 33: Gender-specific cases of PsA in Spain (2022-2036)
Figure 34: Age-specific Cases of PsA in Spain (2022-2036)
Figure 35: Severity-specific Cases of PsA in Spain (2022-2036)
Figure 36: Diagnosed cases of PsA in the UK (2022-2036)
Figure 37: Gender-specific cases of PsA in the UK (2022-2036)
Figure 38: Age-specific Cases of PsA in the UK (2022-2036)
Figure 39: Severity-specific Cases of PsA in the UK (2022-2036)
Figure 40: Prevalent cases of PsA in Japan (2022-2036)
Figure 41: Diagnosed Cases of PsA in Japan (2022-2036)
Figure 42: Gender-specific cases of PsA in Japan (2022-2036)
Figure 43: Age-specific Cases of PsA in Japan (2022-2036)
Figure 44: Severity-specific Cases of PsA in Japan (2022-2036)
